OKYO OKYO Pharma Ltd: Enterprise Value to EBITDA Ratio

OKYO Pharma Inc - graphic logo of issuer OKYO

Stable leadership under Gary Jacob enjoys investor support due to effective cost containment and progress in keratitis research. This EV/EBITDA chart demonstrates a multiple of 0.00, while OKYO Pharma Limited (OKYO) optimizes logistics and testing via third-party contractors. High barriers in the form of molecule patents and strict FDA oversight limit the entry of new players.

OKYO Pharma Ltd - OKYO Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

OKYO (OKYO Pharma Ltd): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price OKYO Pharma|OKYO - Average Forecast Price
- company stock capitalization data:
Market Valuation OKYO|OKYO - Total Enterprise Value
- business book valuation details:
Book Value per Share OKYO Pharma|OKYO - Total Stockholders' Equity|Market Value to Book Value Ratio okyopharma.com|OKYO - Company Total Asset Base
- debt and liquidity data:
Debt to Equity OKYO Pharma Limited|OKYO - Long-Term Liabilities to Capital|Short-Term Debt to Equity OKYO Pharma Ltd|OKYO - Company Aggregate Debts|Debt to Book Value OKYO|OKYO - Long-Term Debt|Company Short-Term Debt OKYO Pharma|Quick Liquidity Indicator okyopharma.com
- financial results and valuation multiples details:
OKYO - Final Profit|Expected Profit OKYO Pharma Limited|OKYO - Market Cap to Net Income|Forward P/E Multiple OKYO Pharma Limited|OKYO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple OKYO Pharma|OKYO - Operating profit EBITDA|Earnings per share for the last twelve months OKYO Pharma|OKYO - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com|OKYO - Net earnings per share growth this year|Earnings growth forecast for next year OKYO Pharma Limited
- revenue and sales details:
OKYO - Revenue and Sales Volume|Company Future Sales Volume OKYO Pharma Limited|OKYO - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio OKYO Pharma Limited|OKYO - Sales Growth YoY (Last Twelve Months)
Fundamental company analysis:OKYO Pharma Inc (OKYO)
Original product of OKYO Pharma

To objectively measure the operational efficiency of OKYO Pharma Limited, it is essential for investors to correlate the total enterprise value with its ability to generate earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple trend, one can assess whether the expenditures on drug synthesis automation and ophthalmologist salaries are justified by the company's market capitalization, accounting for its debt load.

Competitor analysis

Alcon Inc - Enterprise Value to EBITDA Ratio|Bausch + Lomb (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Apellis|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Pharma (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization harrowinc.com|Viridian Therapeutics, Inc. (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LENZ Therapeutics (LENZ)|EV/EBITDA Multiple Oculis AG (OCS)|eyepointpharma.com - Enterprise Value to EBITDA Ratio|KOD: Enterprise Value to Operating Income Before Depreciation|Aldeyra Therapeutics Inc. - EV/EBITDA Multiple|KALA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IRD (Opus Bio) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Adverum (ADVM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization outlooktherapeutics.com|CLSD: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio NBY (NovaBay Pharmaceuticals)|KPRX (Kiora Pharmaceuticals Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALIM (Alimera Sciences Inc)|Total Company Value to Operating Income Before Depreciation Ratio Eyenovia Corp (EYEN)|GHSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Ocuphire Pharma, Inc.|opthea.com (OPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization